Jan 6 (Reuters) - Teoxane SA offered to acquire Revance
Therapeutics ( RVNC ) for a higher price compared to a buyout
offer from Crown Laboratories last month.
Teoxane's proposal provides a 16% premium over the $3.10 per
share price in Revance's merger agreement with Crown
Laboratories on Dec. 9.
(Reporting by Christy Santhosh in Bengaluru; Editing by
Shinjini Ganguli)